Top 50 Ai For Computational Biology in Europe

Bioptimus is developing a universal AI foundation model specifically for biological research, enabling researchers to leverage large-scale data analysis and predictive modeling. This technology addresses the challenge of slow and fragmented discovery processes in biomedicine by providing a cohesive platform for accelerating insights and innovations.

Oxford Drug Design offers an AI‑powered platform that combines deep aaRS biology with proprietary algorithms such as EShape™ and SynthAI™ to perform ligand‑ and structure‑based virtual screening of a 6 M purchasable compound library. The workflow generates synthetically tractable candidates, ranks them with interpretable ML models via AIScape™, and delivers hit‑to‑lead optimization for pharmaceutical, biotech, and academic programs targeting oncology, infectious disease, and other high‑need areas.

Turbine's Simulated Cell™ platform utilizes AI to predict biological responses by simulating experiments across various models, including engineered cell lines and patient samples. This technology accelerates drug development by generating actionable insights in half the time of traditional methods, enabling researchers to identify optimal experimental pathways for novel cancer therapies.

Exazyme is an AI-driven protein design tool that utilizes advanced algorithms to predict protein evolutions, enabling biotech companies to achieve superior outcomes with up to 100 times fewer experiments than traditional screening methods. The platform addresses the inefficiencies in protein optimization by allowing users to evaluate multiple protein properties simultaneously while ensuring data security through on-site deployment or API connections.

The startup has developed an artificial intelligence platform that predicts molecular properties and target affinity using structured perception and feature fusion techniques. This technology streamlines data analysis workflows for biopharma research teams, enabling them to conduct fewer experiments while improving drug discovery outcomes.

NEBULA utilizes dataset-free generative AI and physics-based modeling to create detailed 3D maps of macromolecules, facilitating the identification of potential drug targets. This technology enhances the drug discovery process by providing precise structural insights that are essential for developing new pharmaceuticals.

MultiOmic Health utilizes AI-driven multi-omics analysis and computational systems biology to identify distinct molecular drivers of metabolic syndrome-related diseases. The company develops precision therapeutics and companion diagnostics, enabling shorter clinical trials with higher success rates for conditions such as type 2 diabetes and chronic kidney disease.

Genomate Health develops a computational platform that utilizes artificial intelligence to analyze the unique molecular profiles of cancer patients' tumors, enabling oncologists to identify the most effective targeted therapies. This approach improves treatment outcomes by providing data-backed recommendations that consider multiple genetic alterations, significantly increasing the likelihood of positive patient responses.

Watershed provides a platform for biological data analysis that integrates secure data management, customizable workflows, and supercomputing resources to enable rapid, large-scale analyses across various omics disciplines. By offering a dedicated bioinformatics team and ready-to-use AI tools, Watershed enhances productivity and collaboration for researchers facing the challenges of complex data interpretation.

Rayca Precision utilizes AI-driven bioinformatics platforms, OncoCrest™ and RSA2™, to analyze genomic and transcriptomic data for personalized cancer treatment strategies. The technology addresses the challenge of cancer heterogeneity by providing precise predictions of drug responses and patient outcomes, enabling tailored therapeutic interventions.

The startup develops a drug discovery platform that combines artificial intelligence and synthetic biology to digitize natural diversity and identify potential drug candidates based on their functions. This approach aims to make the discovery of new therapeutics for cancer, metabolic diseases, and infectious diseases more predictable and cost-effective.

Causaly is a generative AI platform that automates knowledge extraction from vast biomedical literature, enabling researchers to identify validated targets and novel biomarkers with high precision. By reducing research time from months to minutes, it enhances productivity by up to 90%, allowing scientists to focus on innovative drug discovery.

DataHowLab is a cloud‑native SaaS platform that creates hybrid bioprocess models by fusing mechanistic equations with machine‑learning trained on existing experimental data. It offers AI‑guided optimal experimental design, transfer learning across molecules and scales, and digital‑twin simulations for both offline scenario testing and real‑time process monitoring via a no‑code interface. The integrated, ISO 27001‑certified data‑management layer centralizes analytics and model deployment, helping bioprocess teams accelerate development cycles and reduce material and labor costs.

AIVIVO LTD develops artificial intelligence systems that generate multi-modal omics data to create OrganoMaps, which connect disease biology with treatment interventions at the organ level. This approach enables the development of targeted medicines for patients by providing insights into organ-specific disease mechanisms.

Turing Biosystems develops a software platform that utilizes interpretable AI and automated reasoning to integrate and analyze multimodal clinical and biological data, addressing high failure rates and adverse immune responses in immunotherapy and cell gene therapy. By optimizing clinical outcomes, the platform enables clinicians and biopharma to deliver more effective and safer treatments tailored to individual patient responses.

Healx provides an AI‑powered platform that integrates genomics, phenotypic and clinical data to identify and prioritize repurposed or optimized compounds for rare disease indications. The system automates in silico screening, predictive efficacy and safety modeling, and workflow orchestration to move candidates from computational prediction to preclinical validation, lowering discovery costs and timelines. It is offered to pharmaceutical, biotech and research consortium partners seeking to expand rare‑disease pipelines.

Aneira applies computational biology and machine learning to provide health and care services for women and families. The company leverages advanced data analysis to offer personalized health insights and support.

SilicoGene offers a no-code platform for health-tech teams to manage the entire AI lifecycle in drug discovery, enabling users to prepare bioinformatics data, train models, and deploy them efficiently. The platform provides on-demand access to cost-effective GPUs and ensures data security through HIPAA-compliant infrastructure, facilitating rapid deployment of AI solutions in real-world applications.

Ingenix provides a multimodal generative AI platform that builds digital twins of drug candidates by integrating genomics, proteomics, imaging, literature, and electronic health records across molecular to population scales. The system delivers detailed, interpretable predictions of clinical efficacy, safety endpoints, and adverse events, and supports natural‑language “what‑if” queries for trial design and candidate prioritization. It is aimed at pre‑clinical, strategic R&D, and clinical development teams in pharmaceutical and biotechnology companies.

Evolvere BioSciences utilizes AI-driven co-evolutionary models to develop next-generation antibiotics that effectively combat bacterial resistance. This approach addresses the critical challenge of antibiotic efficacy in the face of rapidly evolving pathogens.

The startup has developed an artificial intelligence platform for biomarker discovery and sequencing analysis, focusing on extracting biosignatures from single-cell and multi-omics data. This platform enables physicians to efficiently analyze complex disease patterns, reducing data processing time and costs while enhancing insights for patient stratification.

Nabla Bio utilizes biologically informed machine learning and experimental technologies to design antibodies with atomic precision, targeting complex disease mechanisms such as GPCRs and ion channels. The platform enhances drug manufacturability, safety, and efficacy by integrating AI-driven design with empirical measurement of human-relevant drug properties.

CHARM Therapeutics utilizes its proprietary DragonFold technology, which employs 3D deep learning for protein-ligand co-folding, to develop small molecule inhibitors targeting previously undruggable proteins associated with cancer and other diseases. By addressing the challenge of the vast majority of the human proteome remaining undruggable, the company aims to create transformative therapies for patients with high unmet medical needs.

The startup has developed a digital diagnostics platform that utilizes artificial intelligence for genetic analysis and clinical decision support, enhancing the traceability and interoperability of bioinformatics data. This technology enables researchers and clinicians to efficiently access and reuse critical information, thereby expediting the diagnosis process for various diseases.

SeqOne provides a clinical decision support platform that utilizes AI-driven bioinformatics to analyze next-generation sequencing (NGS) data for germline and somatic variants. The platform enhances diagnostic accuracy and efficiency by identifying complex genomic events that standard pipelines often overlook, thereby improving patient outcomes in precision medicine.

Tailwind Biotech provides artificial DNA design services using proprietary artificial intelligence to optimize DNA sequences for bioproduction companies. This technology enhances gene expression and reduces development costs, enabling more efficient and effective genetic engineering processes.

Ensocell utilizes single-cell genomics, AI-driven computational tools, and advanced cell models to identify intervention points for autoimmune, inflammatory, and fibrotic diseases. The company focuses on discovering novel therapeutics to improve treatment outcomes in these challenging health conditions.

The startup employs AI algorithms to analyze genetic data for identifying mutations associated with hereditary diseases. This technology enables healthcare providers to deliver accurate diagnoses and tailored treatment plans for patients with genetic disorders.

Sibylla Biotech develops small molecule folding interfering degraders (FIDs) using its proprietary Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) platform, which employs computer simulations and AI to induce the degradation of target proteins. This approach targets proteins involved in various diseases, addressing the need for new therapeutics in multiple therapeutic areas.

The startup develops gene therapies using artificial intelligence to enhance the design and optimization of genetic constructs. Their technology enables researchers to create more predictable and controllable gene therapies, facilitating faster development for various applications.

CoSyne Therapeutics utilizes polymathic AI and genetic computational systems analysis to expedite the development of pharmaceuticals targeting high-risk brain cancer. By digitizing cellular responses, the company enables medical researchers to create a new class of drugs more efficiently and at a lower cost than traditional methods.

BioStrand utilizes its patented LENSai™ Integrated Intelligence Technology to analyze multi-omics data and accelerate antibody drug discovery through advanced computational methods. This technology addresses the inefficiencies in identifying and prioritizing lead drug candidates by providing rapid insights into drug interactions and predicted efficacy.

The startup develops a computational chemistry platform that utilizes data-driven algorithms and quantum chemistry to predict thermodynamic properties of biochemicals, such as solubility and phase equilibria. This technology provides scientists with a robust computing infrastructure for molecular dynamics simulations, facilitating the acceleration of experimental research.

Provides an AI-powered platform for analyzing complex medical data, including transcriptomics, epigenomics, and proteomics, using modular machine learning techniques. This system accelerates research by delivering fast, high-quality insights for identifying therapeutic targets, biomarkers, and disease mechanisms, reducing time and cost compared to traditional methods.

BioStrand accelerates biotherapeutic discovery with its LENS ai™ platform, a SaaS solution that integrates multi-omics, textual, and structural data. Leveraging proprietary HYFTs® technology and advanced AI, including protein language models and vector search, the platform provides actionable insights to streamline target identification and optimize the drug discovery process.

IONLACE develops the _Radiant_ platform, which combines real-world AI with synthetic biology to enable high-resolution proteomic analysis at scale. This technology addresses the limitation of current methods that can only detect a small fraction of circulating proteins, providing researchers with actionable biomarkers for preventative healthcare.

ScienTek accelerates aptamer discovery for challenging protein targets using an AI-powered platform. Their technology combines in silico screening with in vitro validation to identify and optimize nucleic acid sequences with high binding affinity for next-generation therapeutics.

Deepflare develops a silico antigen discovery platform that utilizes machine learning algorithms to analyze genomic data and identify neoantigens for personalized cancer therapies. This technology enhances immunogenicity modeling and streamlines the drug development process, reducing costs and improving treatment outcomes for pharmaceutical companies.

CubaseBio offers a cloud‑native platform that imports volumetric microscopy and spatial‑omics data, registers multi‑modal signals, and applies deep‑learning segmentation to produce quantitative 3D tissue maps. The system provides an interactive web dashboard, statistical spatial analysis tools, and RESTful/Python APIs for integration with pharmaceutical and academic drug‑discovery pipelines.

This company develops AI-powered tools for drug discovery and medicinal chemistry, focusing on the early phases of drug development. Their platform offers molecular space search, property prediction, and interactive visualization to accelerate the identification and optimization of drug candidates.

Asteria provides a professional platform that features the world's largest curated library of over 500,000 biological strategies, enabling users to leverage 3.8 billion years of evolutionary insights for practical applications. Utilizing AI-driven methodologies, Asteria transforms these nature-inspired strategies into actionable innovations, facilitating the development of solutions across various scientific fields.

The company builds advanced artificial intelligence models, including Gemini for general-purpose tasks and Gemma, an open-source lightweight alternative. Its research spans generative AI, robotics, and scientific domains such as biology, climate science, and physics, delivering tools that support discovery while emphasizing responsible AI development.

Orbion provides an AI-driven platform that analyzes protein sequences to predict stabilizing mutations, truncations, and optimal conditions for structure determination. The system generates editable wet-lab protocols, accelerating structural biology workflows by reducing trial-and-error experimentation for protein expression and purification.

Syngens AS has developed an AI-powered DNA Design Platform that enables precise and predictable DNA engineering for biomanufacturing applications. By optimizing gene expression and constructing novel biological pathways, the platform addresses the limitations of scalability and engineering precision in current biological methods, significantly reducing trial-and-error in experimental processes.

Molab is a biotechnology research company that utilizes an end-to-end discovery platform combining in-silico design, AI/ML methods, and wet lab validation to optimize small molecule drug development. Their technology accelerates hit-to-lead and lead optimization projects by 1.5 to 2 times through proven ADMET predictions and generative molecular design, addressing the inefficiencies in traditional drug discovery processes.

ENPICOM provides a unified bioinformatics platform that integrates scalable data management, machine learning frameworks, and user-friendly analysis tools for lab and data scientists. This solution streamlines biologics discovery and engineering processes, enabling rapid data retrieval and model deployment while reducing reliance on specialized data science support.

Etcembly utilizes AI-driven protein language models to design and optimize T-cell receptors (TCRs) and antibodies, significantly enhancing the precision and safety of immunotherapy candidates for cancer treatment. The startup addresses the urgent need for faster drug discovery by leveraging extensive immune repertoire databases and advanced sequencing technologies to identify novel therapeutic targets.

CrystalsFirst utilizes proprietary structural biology technology and generative AI to enhance crystallographic fragment screening and co-structure determination for challenging protein targets. This approach unlocks previously inaccessible chemical matter, facilitating the development of novel therapeutics for pharmaceutical and biotech companies.

The startup develops bioinformatics tools that utilize artificial intelligence for the identification of drug targets and the evolutionary analysis of protein sequences. By enabling the modeling and computational screening of mutant libraries, the company provides pharmaceutical firms with the capability to discover novel drug candidates in previously unexplored areas.

Aminoverse is a biotech CRO that combines wet lab expertise with artificial intelligence to enhance enzyme research and development, enabling precise enzyme discovery, profiling, and engineering. The company addresses the inefficiencies in traditional enzyme development by providing AI-driven solutions that reduce costs and accelerate the creation of high-performance biocatalysts for various applications.